Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for Candida infections.
Matusik E, Vassal O, Conrad A, Ferry T, Millet A, Dupont D, Grandjean L, Guitton J, Roux S, Bienvenu A-L, Bohé J, Friggeri A, Goutelle S. Matusik E, et al. Among authors: guitton j. Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0099124. doi: 10.1128/aac.00991-24. Epub 2024 Sep 26. Antimicrob Agents Chemother. 2024. PMID: 39324800
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P, Fontaine J, Péron J, Maillet D, Tartas S, Bonnin N, Trillet-Lenoir V, Colomban O, Augu-Denechere D, Freyer G, Tod M. Puszkiel A, et al. Among authors: guitton j. Cancer Chemother Pharmacol. 2023 May;91(5):413-425. doi: 10.1007/s00280-023-04520-z. Epub 2023 Apr 3. Cancer Chemother Pharmacol. 2023. PMID: 37010549 Clinical Trial.
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Varnier R, Puszkiel A, Tod M, Calattini S, Payen L, Lopez J, Guitton J, Schwiertz V, Fontaine J, Peron J, Maillet D, Tartas S, Bonnin N, Colomban O, Augu-Denechere D, Freyer G, You B. Varnier R, et al. Among authors: guitton j. Cancer Chemother Pharmacol. 2023 May;91(5):361-373. doi: 10.1007/s00280-023-04508-9. Epub 2023 Feb 25. Cancer Chemother Pharmacol. 2023. PMID: 36840749 Clinical Trial.
Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.
Alexandre J, Oudard S, Golmard L, Campedel L, Mseddi M, Ladoire S, Khalil A, Maillet D, Tournigand C, Pasquiers B, Goirand F, Berthier J, Guitton J, Dariane C, Joly F, Xylinas E, Golmard JL, Abdoul H, Puszkiel A, Decleves X, Carton E, Thomas A, Vidal M, Huillard O, Blanchet B. Alexandre J, et al. Among authors: guitton j. Clin Pharmacokinet. 2024 Jul;63(7):1025-1036. doi: 10.1007/s40262-024-01396-x. Epub 2024 Jul 4. Clin Pharmacokinet. 2024. PMID: 38963459 Clinical Trial.
Renal toxicity of ifosfamide in children with cancer: an exploratory study integrating aldehyde dehydrogenase enzymatic activity data and a wide-array urinary metabolomics approach.
Febvey-Combes O, Guitton J, Marec-Berard P, Faure-Conter C, Blanc E, Chabaud S, Conjard-Duplany A, Schell M, Derain Dubourg L. Febvey-Combes O, et al. Among authors: guitton j. BMC Pediatr. 2024 Mar 19;24(1):196. doi: 10.1186/s12887-024-04633-1. BMC Pediatr. 2024. PMID: 38504218 Free PMC article.
Reply to: "Is uracil enough for effective pre-emptive DPD testing?".
Thomas F, Launay M, Raymond L, Guitton J, Loriot MA, Chatelut E, Haufroid V, Etienne-Grimaldi MC. Thomas F, et al. Among authors: guitton j. Clin Chem Lab Med. 2024 Aug 15;62(12):e257-e259. doi: 10.1515/cclm-2024-0889. Print 2024 Nov 26. Clin Chem Lab Med. 2024. PMID: 39141832 No abstract available.
Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon-19-deleted advanced NSCLC mutation.
Barthélémy D, Vigneron A, Rousset X, Guitton J, Grolleau E, Raffin M, Balandier J, Lescuyer G, Bardou M, Geiguer F, Couraud S, Bardel C, Viallet J, Benzerdjeb N, Payen L. Barthélémy D, et al. Among authors: guitton j. FEBS Open Bio. 2025 Jan 30. doi: 10.1002/2211-5463.13970. Online ahead of print. FEBS Open Bio. 2025. PMID: 39887892 Free article.
206 results